Chest Medicine
Investigating whether blood type is linked to COVID-19 risk
17 Sep, 2020 | 09:26h | UTCInvestigating Whether Blood Type Is Linked to COVID-19 Risk – JAMA
Commentary on Twitter
Researchers find no relationship between blood type and severe #COVID19, despite early studies suggesting possible higher risk for those with type A. “The basic science on this is extremely weak.” https://t.co/tYreg896DK
— JAMA (@JAMA_current) September 17, 2020
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
COVID-19: Guidance on palliative care from a European Respiratory Society international task force
16 Sep, 2020 | 09:16h | UTC
Months after recovery, COVID-19 survivors often have persistent lung trouble
16 Sep, 2020 | 09:04h | UTCMonths After Recovery, COVID-19 Survivors Often Have Persistent Lung Trouble – NIH Director’s Blog
The lasting misery of coronavirus long-haulers
15 Sep, 2020 | 09:05h | UTCThe lasting misery of coronavirus long-haulers – Nature
NIH launches two trials to test blood thinners in COVID-19 patients
15 Sep, 2020 | 08:56h | UTCNIH launches two trials to test blood thinners in COVID-19 patients – Reuters
Viewpoint: COVID-19 and the path to immunity
14 Sep, 2020 | 01:20h | UTCCOVID-19 and the Path to Immunity – JAMA
Commentary on Twitter
Declines in SARSCoV2 IgG neutralizing Abs raise concerns of susceptibility to reinfection. But acute Ab levels always decline post-infection, and Ab recall responses come from a pool of long-lived memory B cells https://t.co/geGOQkhdw2
— JAMA (@JAMA_current) September 12, 2020
COVID-19 herd immunity: Where are we?
14 Sep, 2020 | 01:18h | UTCCOVID-19 herd immunity: where are we? – Nature Reviews Immunology
Commentary on Twitter
This is one of the most succinct and best written short pieces on herd immunity, what it is and where we are heading with #COVID19.
If not comfortable with math, just get through the first sentences and it’s worth continuing the read. https://t.co/1F3MuQWkfc
— Michael Mina (@michaelmina_lab) September 13, 2020
Updated meta-analysis: Drug treatments for Covid-19
14 Sep, 2020 | 01:04h | UTCDrug treatments for covid-19: living systematic review and network meta-analysis – The BMJ
Commentary on Twitter
https://twitter.com/RSiemieniuk/status/1304447644438327297
A COVID-19 vaccine may be only 50% effective. Is that good enough?
14 Sep, 2020 | 01:03h | UTCA COVID-19 Vaccine May Be Only 50% Effective. Is That Good Enough? – NPR
Meta-analysis: PEEP-induced recruited lung volume measured by volume-pressure curves in ARDS
14 Sep, 2020 | 00:51h | UTC
Commentary on Twitter
PEEP-induced recruited lung volume measured
by VP curves in #ARDS, systematic review: after PEEP increment most pts are recruiters (Vrec > 150ml, 74%). #ICU mortality no significantly different between recruiters/non but evidence very low/publication bias https://t.co/fgyAscoWCf pic.twitter.com/WD02pMycWr— Intensive Care Medicine (@yourICM) September 12, 2020
Cochrane evidence on COVID-19: a round-up
11 Sep, 2020 | 01:47h | UTCCochrane evidence on COVID-19: a round-up – Evidently Cochrane
NSAIDs like ibuprofen not tied to severe COVID-19, death
11 Sep, 2020 | 01:42h | UTCNSAIDs like ibuprofen not tied to severe COVID-19, death – CIDRAP
COVID-19 and pneumothorax: A multicenter retrospective case series
11 Sep, 2020 | 01:39h | UTCCOVID-19 and Pneumothorax: A Multicentre Retrospective Case Series – European Respiratory Journal
Commentary: Another possible COVID complication: ‘Punctured lung’ – CIDRAP
Preliminary randomized trial evaluated recombinant human granulocyte colony–stimulating factor for patients with COVID-19 and lymphopenia
11 Sep, 2020 | 01:36h | UTCInvited Commentary: Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots
Commentary on Twitter
Preliminary findings from a randomized clinical trial suggest that rhG-CSF treatment should be studied in larger trials and in a broader range of patients with #COVID19 https://t.co/SjsoWOkEXg
— JAMA Internal Medicine (@JAMAInternalMed) September 10, 2020
Bacterial and fungal superinfections in critically ill patients with COVID-19
11 Sep, 2020 | 01:28h | UTC
Commentary on Twitter
Bacterial/fungal superinfections in critically ill #COVID19 pts: true prevalence still elusive. Underestimation of late superinfection risk may occur in #ICU; confounding factors also hamper identification of most frequently associated bacteria #COVIDFOAM https://t.co/iDAyOwYekr pic.twitter.com/Z7N4V7tc7q
— Intensive Care Medicine (@yourICM) September 10, 2020
New easy-to-use score for predicting risk of death in patients hospitalized with Covid-19
10 Sep, 2020 | 09:51h | UTCCommentaries: Discovery of four COVID-19 risk groups helps guide treatment – University of Edinburgh AND Expert reaction to a study looking at predicting the risk of death in hospitalised COVID-19 patients – Science Media Centre
Commentary on Twitter
NEW #BMJResearch finds that an easy-to-use score for predicting risk of death in adult patients admitted to hospital with #COVID19 outperforms existing scores and can be used to support treatment decisions @ProfCalumSemple @ISARIC1
https://t.co/2J9S3mqG5h— The BMJ (@bmj_latest) September 10, 2020
Why COVID-19 is more deadly in people with obesity—even if they’re young
10 Sep, 2020 | 09:47h | UTCWhy COVID-19 is more deadly in people with obesity—even if they’re young – Science
Clinical outcomes in young adults hospitalized with COVID-19
10 Sep, 2020 | 09:49h | UTCClinical Outcomes in Young US Adults Hospitalized With COVID-19 – JAMA Internal Medicine
Editorial: Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19
Commentary: Obesity greatest risk factor for young adults with COVID-19 – MedicalXpress
Commentary on Twitter
18 to 34 years old #COVID19 hospitalized outcomes:
✔️21% intensive care,
✔️10% mechanical ventilation
✔️2.7% died.
✔️Morbid obesity, hypertension & diabetes associated with⬆️risks of adverse events.
✔️+ ½ requiring hospitalization: Black or Hispanic⚓️https://t.co/kcs2cery7s pic.twitter.com/ASVB943Bhc
— Medtorek (@Medtorek) September 9, 2020
[Abstract Only] Randomized trial on strategies for tracheostomy decannulation
10 Sep, 2020 | 09:34h | UTC
Commentary on Twitter
New insigths in tracheostomy decannulation. A great pleasure to participate on this study leaded by Gonzalo Hernandez. High-Flow Oxygen with Capping or Suctioning for Tracheostomy Decannulation | NEJM https://t.co/103vhwWlvq @vallhebron @NEJM pic.twitter.com/DzyJSAgn1F
— Oriol Roca (@oriolrocag) September 10, 2020
Interactive calculator for interpreting Covid-19 antibody test results
9 Sep, 2020 | 09:12h | UTCTesting for SARS-CoV-2 antibodies – The BMJ
Commentary on Twitter
#BMJInfographic Try out this new interactive calculator for interpreting covid-19 antibody test results @will_s_t https://t.co/t0Ha5zMlg1 pic.twitter.com/TAjVLog3A1
— The BMJ (@bmj_latest) September 8, 2020
Opinion: “Facial masking for Covid-19 — potential for “variolation” as we await a vaccine”
9 Sep, 2020 | 09:39h | UTC
Commentary on Twitter
Increasing the proportion of SARS-CoV-2 infections that are asymptomatic with the simple public health measure of universal masking might help make the infection less deadly and increase population-level immunity without severe illnesses and deaths. #COVID19 #SARSCoV2
— NEJM (@NEJM) September 8, 2020
AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
9 Sep, 2020 | 09:45h | UTC
Commentary on Twitter
BREAKING: AstraZeneca's #Covid19 vaccine trials have been paused as the company investigates a serious adverse event the occurred in the UK. Not clear if the unexplained illness is linked to the vaccine, or what it was. https://t.co/wGqvvXIBTD
— Helen Branswell 🇨🇦 (@HelenBranswell) September 8, 2020
[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19
9 Sep, 2020 | 09:41h | UTC
Commentary on Twitter
Convalescent Plasma Randomized Controlled Trial (PLACID Trial) in the Management of Moderate #COVID19 (pre-print)
👉 “not associated with reduction in mortality or progression to severe COVID-19”
Link: https://t.co/2ZXnfemsas@GermHunterMD @MackayIM @CT_Bergstrom #IDTwitter pic.twitter.com/yZuOxVhbjL
— Alvin (@alvie_barr) September 8, 2020
Review: Physical medicine and rehabilitation and pulmonary rehabilitation for COVID-19
9 Sep, 2020 | 09:30h | UTC